科研动态期刊摘要
HER2阳性早期乳腺癌化疗降阶梯治疗的5年结局及随机2期PHERGain试验的探索性循环肿瘤DNA分析
Nature Medicine · 2026-10-30
摘要
《自然·医学》，在线发表：2026年10月29日；doi:10.1038/s41591-026-04723-w 对2期PHERGain试验的5年次要分析支持PET引导的适应性策略在HER2阳性早期乳腺癌治疗降阶梯中的临床实用性，并提供了可能为后续治疗方法提供参考的循环肿瘤DNA见解。
English
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial
Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early breast cancer and provides circulating tumor DNA insights that could inform further treatment approaches.